TRENTAL 400 Modified release tablet Ref.[7993] Active ingredients: Pentoxifylline

Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK

Product name and form

TRENTAL 400.

Pharmaceutical Form
Modified release tablet.

Qualitative and quantitative composition

Pentoxifylline 400MG.

Active Ingredient	Description
Pentoxifylline	Pentoxifylline has been shown to increase leukocyte deformability and to inhibit neutrophil adhesion and activation.

List of Excipients
Hydroxyethyl cellulose Povidone Talc Magnesium stearate Hypromellose Macrogol 8000 Erythrosine (E127) Titanium dioxide (E171)

Pack sizes and marketing

Amber glass bottle: 100 or 250 tablets.

Plastic (PE) pots: 100 or 250 tablets.

Blister Pack (Alu/PVC): 10 or 90 tablets.

Marketing authorization holder

Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK

Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK

Marketing authorization dates and numbers

PL 04425/0213

15^th April 2002

Drugs

Drug	Countries
TRENTAL	Austria, Germany, Ecuador, Estonia, Hong Kong, Croatia, Lithuania, Mexico, Netherlands, New Zealand, Singapore, Turkey, United Kingdom

Next: Usage >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.